Phoenix Molecular Designs Raises $2.7M To Develop PMD-026 for Triple-Negative Breast Cancer (TNBC)

Sep. 18
2018

Sept 18, 2018 - PMD-026, the first RSK inhibitor to demonstrate potential disease-modifying properties in TNBC, is now fully funded through IND

Read the full story on PR Newswire here